Bio-Techne (TECH) Stock Price
Bio-Techne Price
Revenue has compounded at 9.3% per year over the past 19 years to 1.22 B USD. Earnings per share have grown at 4.1% per year over the last 19 years. Bio-Techne's net margin stands at 15.0%, down from 24.6% several years earlier. Bio-Techne currently offers a dividend yield of about 0.44%. The payout ratio is around 40% of earnings. The dividend has grown at 9.5% per year over the past 18 years. Analysts set a median price target of 73.00 USD, implying 0.7% above the current price. Of 22 analysts, 7 rate the stock a buy — an overall Hold consensus.
Bio-Techne stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Bio-Techne business model & stock analysis
Frequently asked questions about Bio-Techne
Bio-Techne Corp's business model revolves around providing innovative life science tools and solutions to researchers worldwide. The company focuses on developing and manufacturing high-quality reagents, assays, and instruments used in biomedical research, clinical diagnostics, and pharmaceutical development. With a diverse portfolio, Bio-Techne offers products for gene expression analysis, protein analysis, cell imaging, and stem cell research. Their advanced technologies and expertise enable scientists to accelerate discoveries and enhance their understanding of diseases, ultimately aiding in the development of new therapies. Bio-Techne Corp strives to be at the forefront of scientific advancements by continually investing in research and development initiatives.
Bio-Techne Corp primarily operates in the biotechnology and life sciences industries. Its extensive product portfolio includes cutting-edge solutions for research and diagnostics, spanning the fields of pharmaceuticals, clinical applications, bioprocessing, and academia. With a focus on developing innovative technologies, Bio-Techne Corp delivers products and services that support advancements in areas such as cancer research, stem cell research, immunology, neuroscience, and genetic analysis. As a leading player in these sectors, Bio-Techne Corp continues to make significant contributions to the scientific community and drive progress in the biotechnology field.
Some of the main competitors of Bio-Techne Corp in the market include Thermo Fisher Scientific, Merck KGaA, and Agilent Technologies.
Bio-Techne Corp, formerly known as Techne Corporation, is a leading global life sciences company. Established in 1976, Bio-Techne has a rich history of innovation and scientific discovery. The company develops and manufactures a wide range of cutting-edge products and solutions for the biotechnology and clinical research industries. With a strong focus on research and development, Bio-Techne has consistently brought forth groundbreaking technologies and advanced tools, revolutionizing the understanding and treatment of diseases. Today, Bio-Techne Corp remains at the forefront of the life sciences industry, delivering high-quality products and driving advancements in scientific research worldwide.
Bio-Techne Corp has achieved several significant milestones. The company has successfully expanded its product portfolio, offering a wide range of innovative solutions in life sciences research and diagnostics. Bio-Techne Corp has also witnessed strong financial performance, consistently delivering impressive revenue growth over the years. Moreover, the company has made strategic acquisitions to enhance its capabilities and market presence. With a focus on advanced technologies and a commitment to innovation, Bio-Techne Corp continues to contribute to scientific advancements and improve healthcare outcomes globally.
Bio-Techne Corp is primarily present in various countries and regions worldwide. The company has a widespread global presence, with significant operations and a strong market presence in North America, Europe, and Asia-Pacific. This enables Bio-Techne Corp to serve a diverse customer base and tap into multiple international markets. Along with its headquarters in the United States, Bio-Techne Corp has strategic offices, production facilities, and distribution networks across key countries and regions globally. This expansive global footprint allows the company to effectively deliver its innovative biotechnology solutions and services to customers around the world.
Bio-Techne Corp is a leading global provider of life science products and solutions. The company values innovation, scientific excellence, and customer-centricity. Bio-Techne Corp's corporate philosophy revolves around advancing scientific discoveries and improving human health. With a strong commitment to research and development, Bio-Techne Corp focuses on providing cutting-edge tools and technologies to support the life science community. By fostering collaboration and investing in breakthrough technologies, the company aims to accelerate scientific progress and enable researchers to make significant contributions in the fields of genomics, proteomics, and cell biology. Overall, Bio-Techne Corp is dedicated to driving innovation and making a positive impact in the life science industry.
Analysts currently set an average price target of 65.78 USD for the Bio-Techne stock (median: 73.00 USD), implying -9.3 % versus the latest price. The consensus is based on 22 analyst ratings.
22 analysts currently rate the Bio-Techne stock: 7 recommend buying, 15 holding and 0 selling.
Converted at the current exchange rate, the Bio-Techne share trades at 64.60 EUR (72.51 USD).
The Bio-Techne share (TECH) is listed on 4 stock exchanges, including: NASDAQ (TECH), Frankfurt (TE1.F), München (TE1.MU), Düsseldorf (TE1.DU).
Bio-Techne Corp is a leading provider of innovative products for the biotechnology and clinical diagnostics industry. The company offers a wide range of products and services for protein research, cell analysis, microscopy, genomics, and clinical diagnostics. Protein research: Bio-Techne offers proteins, antibodies, reagents, and instruments for signal pathway research, protein expression, and function. Well-known brands in this field include R&D Systems, Novus Biologicals, Tocris, and ProteinSimple. Cell analysis: For cell analysis, Bio-Techne provides a wide range of products including cell analysis devices, reagents, and instruments for flow cytometry, cell culture, and microscopy. BioLegend is the leading brand for cell analysis products from Bio-Techne. Microscopy: Bio-Techne also offers a wide range of microscopy products for cell and tissue analysis. This includes endoscopes, cameras, microscopes, imaging software, and accessories. Brands in this field include Nikon Instruments, Zeiss, and Lumera. Genomics: Bio-Techne's genomics offering includes custom gene synthesis, antisense oligonucleotides, miRNA inhibitors, as well as PCR, qPCR, and sequencing kits and reagents. The company also provides comprehensive genomics services including analysis, sequencing, and data analysis. Clinical diagnostics: Bio-Techne provides solutions for clinical diagnostics, including IVD reagents, custom biomarker development and services, immunohistochemistry test systems, as well as devices and instruments for clinical sample submission. Brands in this field include R&D Systems, Novus Biologicals, and Exosome Diagnostics. Summary: Overall, Bio-Techne Corp offers a wide range of solutions for the biotechnology and clinical diagnostics industry. With its leading brands and extensive range of products and services, the company has established itself as a key player in this field. Through continuous product and service development and innovation, Bio-Techne is able to maintain its market share and further expand its business in various niche markets.
The revenue of Bio-Techne is 1.22 B USD. This figure is based on current financial data and reflects the company's business performance.
The profit of Bio-Techne is 181.86 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Bio-Techne is currently 62.61. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bio-Techne stock.
The price-to-sales ratio (P/S) of Bio-Techne is currently 9.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bio-Techne stock.
The Eulerpool Quality Score for Bio-Techne is 4/10.
The ISIN of Bio-Techne is US09073M1045. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Bio-Techne is A12ENG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Bio-Techne is TECH. The ticker symbol is used to trade Bio-Techne shares on the stock exchange.
Bio-Techne stock
Bio-Techne Peer Group
Bio-Techne Ticker
Bio-Techne FIGI
All fundamentals and in-depth analysis of Bio-Techne
Our stock analysis for Bio-Techne stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio-Techne. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.